| NCT03764098 |
Guanfacine |
Yes |
Class A |
Adrenoceptors |
Mechanistic
Evaluation of Guanfacine on Drinking Behavior in Women and Men With
Alcohol Use Disorders |
| NCT04827056 |
Dexmedetomidine |
Yes |
Class A |
Adrenoceptors |
Effect
of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol
Interaction Study |
| NCT04135846 |
Doxazosin |
Yes |
Class A |
Adrenoceptors |
Alpha-1
Blockade for Alcohol Use Disorder (AUD) |
| NCT03137082 |
Guanfacine |
Yes |
Class A |
Adrenoceptors |
Guanfacine to
Reduce Relapse Risk in Women With Alcohol Use Disorder
(AUD) |
| NCT04793685 |
Prazosin |
Yes |
Class A |
Adrenoceptors |
Prazosin for
Alcohol Use Disorder With Withdrawal Symptoms |
| NCT05317546 |
Cannabidiol |
Yes |
Class A |
Canabiniod |
Cannabidiol in
Youth Alcohol Use Disorder |
| NCT04873453 |
Cannabidiol |
Yes |
Class A |
Canabiniod |
CBD for the
Treatment of Alcohol Use Disorder |
| NCT05613608 |
Cannabidiol |
Yes |
Class A |
Canabiniod |
Alcohol Use
Disorder and Cannabidiol |
| NCT05159830 |
Cannabidiol |
Yes |
Class A |
Canabiniod |
Cannabidiol for
Reducing Drinking in Alcohol Use Disorder |
| NCT05387148 |
Cannabidiol |
Yes |
Class A |
Canabiniod |
The Efficacy
and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol
Dependence |
| NCT05860699 |
Cannabidiol |
Yes |
Class A |
Canabiniod |
Cannabidiol as
an add-on Treatment During Inpatient Alcohol Cessation in Patients With
Severe Alcohol Use Disorder: a Phase ii Trial |
| NCT04603781 |
Cannabidiol |
Yes |
Class A |
Canabiniod |
CBD Oil for
Reducing Emotional Impact of COVID-19 |
| NCT05781009 |
Pregnenolone |
Yes |
Class A |
Canabiniod |
Pregnenolone
for the Treatment of Alcohol Use Disorder |
| NCT02461927 |
Naltrexone (+ Ketamine) |
Yes |
Class A |
Opioid |
Ketamine for the Rapid Treatment of Major Depressive Disorder and
Alcohol Use Disorder |
| NCT05919017 |
Naltrexone |
Yes |
Class A |
Opioid |
Exploring the PK of
Different Doses of Naltrexone in Patients With AUD |
| NCT05028062 |
Naltrexone |
Yes |
Class A |
Opioid |
Naltrexone in AUD
Reward Drinkers |
| NCT05656534 |
Suvorexant |
Yes |
Class A |
Orexin |
Orexin Receptor
Antagonists as Modulators of Threat Sensitivity in Individuals With
Alcohol Use Disorder |
| NCT05312008 |
Oxytocin |
Yes |
Class A |
Oxytocin |
Does Oxytocin Alter
Tolerance to or Motivation for Alcohol |
| NCT03878316 |
Oxytocin |
Yes |
Class A |
Oxytocin |
Intranasal Oxytocin
for the Treatment of Alcohol Use Disorder |
| NCT04071119 |
Oxytocin |
Yes |
Class A |
Oxytocin |
Alcohol and
Cigarette Craving During Oxytocin Treatment |
| NCT04523922 |
Oxytocin |
Yes |
Class A |
Oxytocin |
Oxytocin to Enhance
Integrated Treatment for AUD and PTSD |
| NCT03846505 |
Oxytocin |
Yes |
Class A |
Oxytocin |
Oxytocin to Enhance
Alcohol Behavioral Couple Therapy (ABCT) |
| NCT05093296 |
Oxytocin |
Yes |
Class A |
Oxytocin |
Oxytocin and
Naltrexone: Investigation of Combined Effects on Stress- and Alcohol
Cue-induced Craving in Alcohol Use Disorder |
| NCT05674929 |
BPL-003 |
Yes |
Class A |
Serotonin |
An Open-Label,
Single Dose Study in Patients With Alcohol Use Disorder |
| NCT05913752 |
CMND-100 |
Yes |
Class A |
Serotonin |
A First in Human
Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD)
Subjects |
| NCT05474989 |
LSD |
Yes |
Class A |
Serotonin |
LSD Treatment for
Persons With Alcohol Use Disorder |
| NCT05943665 |
MDMA |
Yes |
Class A |
Serotonin |
MDMA for AUD/PTSD
Comorbidity |
| NCT05709353 |
MDMA |
Yes |
Class A |
Serotonin |
MDMA-assisted Prolonged
Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic
Stress Disorder |
| NCT05416229 |
Psilocybin |
Yes |
Class A |
Serotonin |
Psilocybin-assisted Therapy for Treatment of Alcohol Use
Disorder |
| NCT04410913 |
Psilocybin |
Yes |
Class A |
Serotonin |
Pilot Trial of
Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use
Disorder |
| NCT05646303 |
Psilocybin |
Yes |
Class A |
Serotonin |
Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder
(AUD) |
| NCT04141501 |
Psilocybin |
Yes |
Class A |
Serotonin |
Clinical and
Mechanistic Effects of Psilocybin in Alcohol Addicted
Patients |
| NCT04718792 |
Psilocybin |
Yes |
Class A |
Serotonin |
Psilocybin for
Treatment of Alcohol Use Disorder: a Feasibility Study |
| NCT04620759 |
Psilocybin |
Yes |
Class A |
Serotonin |
Psilocybin
Treatment of Major Depressive Disorder With Co-occurring Alcohol Use
Disorder |
| NCT05421065 |
Psilocybin |
Yes |
Class A |
Serotonin |
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use
Disorder |
| NCT04066192 |
Brexpiprazole |
Yes |
Class A |
Serotonin & Dopamine |
Brexpiprazole in Alcohol Use Disorder |
| NCT03526354 |
Brexpiprazole |
Yes |
Class A |
Serotonin & Dopamine |
Brexpiprazole Study |
| NCT05520775 |
Semaglutide |
Yes |
Class B1 |
Glucagon |
Semaglutide for
Alcohol Use Disorder |
| NCT05892432 |
Semaglutide |
Yes |
Class B1 |
Glucagon |
Clinical Trial
of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder
(AUD) |
| NCT05891587 |
Semaglutide |
Yes |
Class B1 |
Glucagon |
Semaglutide
Therapy for Alcohol Reduction - Tulsa |
| NCT05895643 |
Semaglutide |
Yes |
Class B1 |
Glucagon |
Does Semaglutide
Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid
Obesity? |
| NCT04679142 |
Baclofen |
Yes |
Class C |
GABA |
Baclocur
Post-Authorisation Safety Study in Real-life Settings in
France |
| NCT04831684 |
GET73 |
Yes |
Class C |
Glutamate |
Novel mGluR5 Modulator
Effects on Alcohol Drinking and MRI Outcomes |
| NCT04218357 |
Probenecid |
Yes |
Class T |
Taste |
Probenecid as
Medication for Alcohol Use Disorder |
| NCT05870111 |
Citicoline |
No |
|
|
Citicoline in Youth Alcohol Use
Disorder |
| NCT03896516 |
GLWL-01 |
No |
|
|
Manipulating Ghrelin Signaling Via
GOAT Inhibition in Alcohol Use Disorder |
| NCT05830708 |
Lactobacillus sp. Probiotic |
No |
|
|
The Efficacy of
Probiotics for the Treatment of Alcohol Use Disorder Among Adult
Males |
| NCT05178069 |
Lactobacillus Rhamnosus GG |
No |
|
|
LGG
Supplementation in Patients With AUD and ALD |
| NCT05807139 |
Spironolactone |
No |
|
|
Spironolactone in Alcohol Use
Disorder (SAUD) |
| NCT05134857 |
Zonisamide |
No |
|
|
The Zonisamide and Reinforcement
for Reducing Alcohol Use (ZARRA) Study |
| NCT04015869 |
Allopregnanolone |
No |
|
|
Effect of Allopregnanolone
on Stress-induced Craving |
| NCT05223829 |
Brexanolone |
No |
|
|
Utility of Brexanolone to Target
Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress
Disorder |
| NCT04084860 |
CI-581a |
No |
|
|
The Role of Brief Potent
Glutamatergic Modulation in Addressing Problem Drinking |
| NCT05042102 |
Donepezil |
No |
|
|
Donepezil and Cognitive Training
for Alcohol Use Disorder (AUD) |
| NCT04098302 |
Dutasteride |
No |
|
|
Dutasteride Treatment for
Reducing Heavy Drinking in AUD: Predictors of Efficacy |
| NCT04527185 |
Endotoxin |
No |
|
|
Effect of Endotoxin on Alcohol
Consumption |
| NCT05414240 |
Ibudilast |
No |
|
|
Ibudilast for Treating Alcohol Use
Disorder |
| NCT05661669 |
Ketamine |
No |
|
|
Ketamine for the Treatment for
Alcohol Use Disorder in the ED |
| NCT04616781 |
Ketone Ester |
No |
|
|
Ketone Ester Intervention in
Alcohol Use Disorder |
| NCT02989662 |
Mifepristone |
No |
|
|
INIA Stress and Chronic Alcohol
Interactions: Glucocorticoid Antagonists in Heavy
Drinkers |
| NCT03707951 |
N-acetylcysteine |
No |
|
|
N-Acetylcysteine for
Adolescent Alcohol Use Disorder |
| NCT05408247 |
N-acetylcysteine |
No |
|
|
A Randomised Controlled
Trial of N-acetylcysteine for the Management of Alcohol Use
Disorder |
| NCT05899660 |
Omega-3 |
No |
|
|
Impact of Omega 3 in Alcohol Use
Disorder |
| NCT03864146 |
Pioglitazone |
No |
|
|
Pioglitazone for the Treatment
of Alcohol Use Disorder |
| NCT05107765 |
Pioglitazone |
No |
|
|
Effects of Pioglitazone on
Stress Reactivity and Alcohol Craving |
| NCT04322305 |
Pregabalin |
No |
|
|
Pregabalin Trial for the Treatment
of Alcohol Use Disorder |
| NCT02884908 |
Pregabalin |
No |
|
|
Pharmacogenetic Treatment With
Anti-Glutaminergic Agents for Comorbid PTSD & AUD |
| NCT04331288 |
PT150 |
No |
|
|
Effects of Ethanol on the
Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK
Study) |
| NCT04232800 |
Riboflavin |
No |
|
|
Riboflavin for Glutamate Reduction
in Alcohol Withdrawal |
| NCT05902754 |
Sulforaphane |
No |
|
|
Broccoli Extract Supplementation
in Older Adults With Alcohol Use Disorder |
| NCT03904498 |
Tolcapone |
No |
|
|
COMT Inhibition Among Individuals
With Comorbid AUD/ADHD |
| NCT03176953 |
Topiramate |
No |
|
|
Topiramate and Prolonged
Exposure |
| NCT04770493 |
Lamotrigine |
No |
|
|
Enhancing the Effects of
Alcohol Treatment With Lamotrigine |